Immunic Total Other Income Expense Net from 2010 to 2026
| IMUX Stock | USD 1.19 0.00 0.00% |
Total Other Income Expense Net | First Reported 2012-09-30 | Previous Quarter 414 K | Current Value 4 M | Quarterly Volatility 1.7 M |
Macro event markers
Use the financial statements timeline for Immunic to frame performance drivers and balance sheet structure. It connects Depreciation And Amortization of 159.6 K, Interest Expense of 730.2 K or Other Operating Expenses of 64.7 M and ratios such as Price To Sales Ratio of 17.3 K, Dividend Yield of 0.0064 or Days Sales Outstanding of 0.0 with Immunic Valuation and Volatility context.
Immunic | Total Other Income Expense Net | Build AI portfolio with Immunic Stock |
Analyzing Immunic's Total Other Income Expense Net over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Total Other Income Expense Net has evolved provides context for assessing Immunic's current valuation and future prospects.
Latest Immunic's Total Other Income Expense Net Growth Pattern
Below is the plot of the Total Other Income Expense Net of Immunic over the last few years. It is Immunic's Total Other Income Expense Net historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunic's overall financial position and show how it may be relating to other accounts over time.
| Total Other Income Expense Net | 10 Years Trend |
|
Total Other Income Expense Net |
| Timeline |
Immunic Total Other Income Expense Net Regression Statistics
| Arithmetic Mean | 1,680,812 | |
| Coefficient Of Variation | 164.39 | |
| Mean Deviation | 2,318,977 | |
| Median | 577,000 | |
| Standard Deviation | 2,763,057 | |
| Sample Variance | 7.6T | |
| Range | 8.8M | |
| R-Value | 0.29 | |
| Mean Square Error | 7.4T | |
| R-Squared | 0.09 | |
| Significance | 0.26 | |
| Slope | 159,820 | |
| Total Sum of Squares | 122.2T |
Immunic Total Other Income Expense Net History
Stock Overview, Methodology & Data Sources
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. t and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 65 people. Operational efficiency and capital allocation discipline are central to the long-run profile of Immunic. The company is currently operating at a loss. Immunic has a market cap of 152.64 M, ROE of -16.53%.
Methodology
Unless otherwise specified, financial data for Immunic is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Immunic (USA Stocks:IMUX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Inputs are aggregated from public filings and market reference sources and public institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Certain values may not reflect real-time changes. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Immunic may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Michael Smolkin - Member of Macroaxis Board of DirectorsAlso Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.More Resources for Immunic Stock Analysis
Reviewing Immunic commonly begins with financial statements and performance trends. Key ratios help frame profitability, efficiency, and growth context for Immunic Stock. Outlined below are key reports that provide context for Immunic Stock:Compare Immunic against competitors using Immunic Correlation. The view adds relative comparison context. For a practical introduction to investing in Immunic Stock, check out our How to Buy Immunic guide.Immunic currently shows ROE of -16.53%, market cap of 152.64 Million. Immunic analysis should be paired with portfolio risk and diversification tools before adjusting allocations. Within the Healthcare space, Immunic peer comparison and risk tools below help frame relative strengths and weaknesses. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
The market value of Immunic is measured differently than book value, which reflects Immunic accounting equity. Immunic's market capitalization is 152.64 M. The 12.72 P/B ratio shows Immunic carries a substantial premium over its balance-sheet equity. Enterprise value stands at 139.69 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
The concept of value for Immunic differs from its quoted price, since each reflects a different lens. For Immunic, key inputs include a P/B ratio of 12.72, and ROE of -16.53%. Immunic market price reflects the current exchange level formed by active bids and offers.